Results 131 to 140 of about 81,374 (255)

Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The approval of new pharmacotherapies for metabolic dysfunction‐associated steatohepatitis (MASH) presents a critical need for value assessment. We evaluated the cost‐effectiveness of resmetirom, semaglutide and tirzepatide for U.S. adults with MASH and F2–F3 fibrosis.
Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian   +5 more
wiley   +1 more source

Burden of non-cancer comorbidities and mortality in chronic pancreatitis: a retrospective cohort study. [PDF]

BMJ Open Gastroenterol
Quammie S, Rashid A, Munyal R, Nicholson ES, Clarke C, Venkatachalapathy SV, Crooks CJ, Aithal GP, Aravinthan AD, DEMISTIFI Consortium.   +9 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Enhancing Preclinical Rigor: Evaluating Robustness and Numerical Stability in a Chronic Pancreatitis Mouse Model. [PDF]

Ann N Y Acad Sci
Thämlitz A, Khan MI, Schulz B, Pilch L, Vollmar B, Zechner D.   +5 more
europepmc   +1 more source

Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world effectiveness, safety and patient‐reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost‐constrained setting. Methods This 30‐week, prospective, multicentre, non‐interventional study enrolled adults with T2DM initiating ...
Arshad Hussain, Muhammad Umar Wahab, Saleem Qureshi, Umar Yousaf Raja, Atif Munir, Shahnawaz Gardezi, Musarrat Iqbal, Bilal Afzal, Muhammad Daoud Butt, Siew Chin Ong   +9 more
wiley   +1 more source

Endoscopic ultrasound diagnosis and management of mass-forming chronic pancreatitis with situs inversus. [PDF]

Endoscopy
Ma J, Zhang N, Jiang W, Jin Z, Wang K.
europepmc   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris, Djordje S. Popovic, Alexandros L. Liarakos, Alexandros Briasoulis, Nikolaos Papanas, Theocharis Koufakis   +5 more
wiley   +1 more source

Chronic pancreatitis associated with genetic mutation and drug-resistant epilepsy. [PDF]

Prz Gastroenterol
Koczyńska MW, Ewa Małecka- W, Stefańczyk L.   +2 more
europepmc   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Atraumatic Splenic Rupture Caused by Splenic Vein Thrombosis in a Patient With Chronic Pancreatitis. [PDF]

Cureus
Takenaka R.
europepmc   +1 more source